stockrow
Friday 6 November 2026
Export CELC’s income statement to Excel — free account
Celcuity, Inc.
CELC Healthcare Biotechnology
- EPS
- −38.5%
- Free cash flow
- −53.3%
- Total debt
- +658.7%
Quarter to June 2026, against a year earlier
66.82
2.78
+4.34%
Follow CELC
Alert me
Celcuity, Inc. (CELC) Debt to equity
Celcuity, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was −58.9×, down 62.1× from fiscal 2025 (3.2×). Over the past ten years it has ranged from 0.0× (fiscal 2017) to 3.2× (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 0.0× and below the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 3.2× | 278.65% |
| FY2024 | 0.8× | 218.98% |
| FY2023 | 0.3× | 1.34% |
| FY2022 | 0.3× | 22.83% |
| FY2021 | 0.2× | 30,314.29% |
| FY2020 | 0.0× | 0.00% |
| FY2019 | 0.0× | (12.50%) |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | −58.9× | — |
| Mar 2026 | 6.0× | 88.79% |
| Dec 2025 | 3.2× | 16.90% |
| Sep 2025 | 2.7× | 22.39% |
| 37 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.2×
Ten-year median
0.0×
Current reading's percentile
100
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| CELC Celcuity, Inc. | −58.9× |
| VRDN Viridian Therapeutics, Inc. compare | 0.0× |
| IDYA IDEAYA Biosciences, Inc. compare | 0.0× |
| ELVN Enliven Therapeutics, Inc. compare | 0.0× |
| DNLI Denali Therapeutics Inc. compare | 0.0× |
| DYN Dyne Therapeutics, Inc. compare | 0.3× |
| VKTX Viking Therapeutics, Inc. compare | 0.4× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 0.7× |
| TLX Telix Pharmaceuticals Limited compare | 1.2× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)